Last reviewed · How we verify
Pembrolizumab plus denosumab
At a glance
| Generic name | Pembrolizumab plus denosumab |
|---|---|
| Also known as | Keytruda and Xgeva |
| Sponsor | Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers (PHASE1)
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (PHASE2)
- Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: